Comparison of Postoperative QoR-15 Scores Between Propofol and Remimazolam

• Status: Recruiting
• Trial end date: 2022-08-04
• Target enrollment: 0
• Participant gender: All

Summary

Remimazolam is a ultra-short-acting benzodiazepine, and unlike conventional benzodiazepine drugs, it is rapidly metabolized in plasma and not accumulates in the body for long periods of infusion or even with high dose administration. In addition, it has no injection pain and infusion syndrome compared with propofol. In particular, there is no study to investigate overall postoperative functional recovery via QoR-15 in patients receiving TIVA using remimazolam. Therefore, rhe purpose of the study is to compare poetoperative quality of recovery (QoR)-15 scores according to the use of anesthetics for total intravenous anesthesia in the cervical spine surgery with intraoperative neurophysiological monitoring.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gangnam Severance Hospital

Criteria

Inclusion Criteria:

• Adult patients who aged 20-70 years with ASA-PS 1-3,

• diagnosed of ossification of the posterior longitudinal ligament or cervical spondylotic myelopathy

• intraoperative neurophysiological monitoring.

Exclusion Criteria:

• Tolerance or hypersensitivity to benzodiazepine or propofol

• Dependence or addiction to psychotropic drugs or alcohol

• Pregnant women, subjects who lack the ability to make decisions and susceptible to voluntary participation decisions